The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).
 
Pamela L. Kunz
Stock and Other Ownership Interests - Guardant Health
Consulting or Advisory Role - Acrotech Biopharma; Advanced Accelerator Applications/Novartis; Amgen; Crinetics Pharmaceuticals; Genentech/Roche; HUTCHMED; Ipsen; Lexicon; Natera; RayzeBio; Sun Pharma
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Brahms (Inst); Ipsen (Inst); Lexicon (Inst); Xencor (Inst)
 
Noah Graham
No Relationships to Disclose
 
Paul J. Catalano
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Regeneron (Inst)
 
Halla Nimeiri
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Advanced Accelerator Applications; Ipsen
Consulting or Advisory Role - Ipsen; Merck; Taiho Pharmaceutical
Research Funding - Aduro Biotech (Inst); Forty seven (Inst); Genentech/Roche (Inst); Merck (Inst); Newlink Genetics (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
Other Relationship - AstraZeneca; CytomX Therapeutics; Hutchison MediPharma; Silenseed; Taiho Pharmaceutical; Terumo Clinical Supply
 
Teri A. Longacre
No Relationships to Disclose
 
Carlos J. Suarez
No Relationships to Disclose
 
Daniel Rubin
Consulting or Advisory Role - Roche/Genentech
Research Funding - GE Healthcare (Inst); Philips Healthcare (Inst)
Patents, Royalties, Other Intellectual Property - Several pending patents on AI algorithms (Inst)
 
James C. Yao
No Relationships to Disclose
 
Matthew H. Kulke
Research Funding - Bristol Myers Squibb (Inst); tersera (Inst)
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Ipsen; Novartis; Perthera; Valar Labs
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - Halozyme
Other Relationship - FibroGen
 
James Christopher Shanks
No Relationships to Disclose
 
Manisha H. Shah
Research Funding - Lilly (Inst); Merck (Inst)
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; Seagen
 
Edmond L. Schmulbach
No Relationships to Disclose
 
Diane Lauren Reidy
Honoraria - Novartis
Consulting or Advisory Role - Advanced Accelerator Applications; Chiasma; ITM Oncologics; Lexicon
Research Funding - Ipsen; Merck; Novartis
 
Jonathan R. Strosberg
Consulting or Advisory Role - Tersera
Speakers' Bureau - Ipsen
Research Funding - ITM Solucin (Inst); Novartis (Inst)
 
Terence Z. Wong
Consulting or Advisory Role - GE Healthcare
Research Funding - Blue Earth Diagnostics (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - GE Healthcare
 
Peter J. O'Dwyer
Consulting or Advisory Role - Genentech
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - Dai-ichi Sankyo; Lilly
 
Al Bowen Benson
Consulting or Advisory Role - Abbvie; Apexigen; Array BioPharma; Artemida Pharma; Boston Scientific; Bristol-Myers Squibb; HalioDx; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Natera; Pfizer; Samsung Bioepis; Therabionic; Xencor
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Elevar Therapeutics (Inst); Infinity Pharmaceuticals (Inst); ITM Solucin (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Rafael Pharmaceuticals (Inst); st pharm (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Tyme Inc (Inst); Xencor (Inst)